Nebido® (testosterone undecanoate) is contraindicated in men with androgen-dependent carcinoma of the prostate. Careful and regular monitoring of the prostate gland must be performed in accordance with recommended methods (digital rectal examination and serum PSA measurement) in patients receiving testosterone replacement therapy, especially in elderly and at risk patients. Local guidelines for safety monitoring should be taken into consideration. Please refer to the Summary of Product Characteristics for full details http://www.bayer.co.uk/en/businesses/bayer-healthcare/bayer-healthcare-pharma/our-products.
Report Adverse Events
Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk.
Adverse events should also be reported to Bayer plc, Tel: 01182063500, Fax: 01182063703, Email: firstname.lastname@example.org.
If You Want to Report a Quality Complaint
Please report any quality complaint to Bayer Plc, Email: email@example.com